Full-Time

Director – Facilities Engineering

Posted on 10/25/2024

ProKidney

ProKidney

51-200 employees

Develops cell therapy for chronic kidney disease

Biotechnology
Healthcare

Expert

Winston-Salem, NC, USA

Category
Construction Management
Building Services Engineering
Architecture & Civil Engineering

You match the following ProKidney's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BS in Engineering preferred
  • 10+ years of pharma (or regulated industry) experience with 8+ years in professional and technical staff management with accountability for objectives and subsequent evaluation
  • 10+ years of experience in facilities, maintenance and/or engineering
  • Solid background in facilities and project management
  • Strong leadership and communication skills
  • Ability to adapt to changing priorities and resource challenges
  • Organized and capable of providing concise, logical recommendations
Responsibilities
  • Develop and maintain procedures for design, construction, and commissioning of projects
  • Manage project planning, including cost estimates and contracts
  • Direct personnel and contractors for equipment installation and modifications
  • Serve as the subject matter expert on engineering systems
  • Collaborate with departments like Manufacturing and Quality to identify improvement projects
  • Secure approvals for project justifications and manage engineering activity schedules
  • Ensure compliance with cGMP during construction and facilitate documentation processes
  • Maintain as-built documentation for all facilities
  • Provide troubleshooting support and oversee environmental compliance efforts
  • Track and communicate performance metrics
  • Supervise engineering staff, ensuring quality of work and training
  • Stay updated on industry standards and trends
  • Build relationships with design and construction partners
  • Ensure the quality of work performed by external partners
  • Manage equipment handover to the maintenance team

ProKidney focuses on developing a new treatment for Chronic Kidney Disease (CKD) using a cell therapy called rilparencel. This therapy aims to help preserve kidney function in patients with advanced CKD, potentially delaying or eliminating the need for dialysis, which is a common and life-changing procedure for many patients. ProKidney is currently in the late stages of clinical trials, and early results indicate that rilparencel may effectively maintain kidney function. What sets ProKidney apart from its competitors is its specific focus on CKD and its unique approach to treatment through cell therapy, targeting a significant and underserved patient population. The company's goal is to provide a new therapeutic option that can improve the quality of life for millions of CKD patients, ultimately transforming their treatment experience.

Company Size

51-200

Company Stage

IPO

Total Funding

$559.3M

Headquarters

Winston-Salem, North Carolina

Founded

2015

Simplify Jobs

Simplify's Take

What believers are saying

  • ProKidney raised $140 million, boosting clinical trials and R&D for rilparencel.
  • The FDA's approval of similar therapies may ease rilparencel's regulatory pathway.
  • Growing personalized medicine trends favor ProKidney's cell therapy approach.

What critics are saying

  • ProKidney's canceled Greensboro expansion may harm its reputation and stakeholder trust.
  • Increased manufacturing expenses could strain financial resources, affecting development pace.
  • Reliance on public offerings for capital may indicate potential cash flow issues.

What makes ProKidney unique

  • ProKidney is pioneering rilparencel, a novel cell therapy for CKD.
  • Rilparencel aims to delay or eliminate the need for dialysis in CKD patients.
  • ProKidney targets an underserved CKD market, addressing a critical treatment gap.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

-1%

2 year growth

-1%
Stock Titan
Jan 7th, 2025
ProKidney to Present at the 43rd Annual J.P. Morgan Healthcare Conference

WINSTON-SALEM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) ("ProKidney"), a late clinical-stage biotech company focused on the development of a first-in-class cell therapy candidate for chronic kidney disease (CKD), today announced that ProKidney's CEO, Bruce Culleton, M.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference.

Rhino Times
Nov 25th, 2024
The Best Laid Plans Of Mice And ProKidney...

In June 2023, ProKidney announced that the company planned to invest $485 million in a Greensboro biomedical factory that would create roughly 330 jobs - with those jobs averaging just under $75,000 a year.

Business North Carolina
Nov 22nd, 2024
ProKidney buys Winston-Salem land after passing on Greensboro deal

ProKidney's purchasing the buildings from Breit SE Industrial Propco, also known as Blackstone Real Estate Income Trust.

WFMY News 2
Nov 19th, 2024
ProKidney no longer coming to Greensboro, Chamber of Commerce confirms

ProKidney had previously planned to expand operations into Greensboro.

Bizjournals
Oct 23rd, 2024
Power 50 Five to Watch: Bruce Culleton, ProKidney

Less than six months after joining the company, Dr. Bruce Culleton was appointed CEO of ProKidney, a regenerative medicine that made one of the largest manufacturing investments in Triad history.

Winston-Salem Journal
Aug 9th, 2024
ProKidney reports higher expenses as manufacturing resumes

On Sept. 8, ProKidney confirmed it will expand its Winston-Salem laboratory, manufacturing and office operations by making a $21 million capital investment and creating 50 jobs by 2027.

CSIMarket
Jun 18th, 2024
#ProKidney Corp Raises $140 Million in Public and Direct Offering, Fueling Breakthroughs in Chronic Kidney Disease Therapeutics

ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering<br/>ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering, raising a total of $140 million.<br/>In the public offering, ProKidney sold 46,886,452 Class A ordinary shares to the public at a price of $2.42 per share. This includes an additional 4,142,232 Class A ordinary shares that were sold as a result of the underwriters exercising their option to purchase additional shares. The total value of the shares sold in the public offering, before applicable underwriting discounts and commissions, amounts to $113.5 million.<br/>

Stock Titan
Jun 10th, 2024
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering | $PROK Stock News

ProKidney (NASDAQ: PROK) unveils $125M public offering to boost clinical trials & R&D. Interested investors include entities tied to the chairman. Learn more.

Business Wire
May 28th, 2024
Revolutionary Chronic Kidney Disease Therapeutics Company ProKidney to Become Publicly Traded via Business Combination with Social Capital Suvretta Holdings Corp. III

ProKidney LP (“ProKidney”), a leading clinical-stage cellular therapeutics company focused on chronic kidney disease (“CKD”), has entered into a defin

Rhino Times
May 15th, 2024
Stock Of Greensboro's Future Job Creator, ProKidney, Shows A Pulse

In mid-2023, ProKidney Corp., a medical tech company based out of Winston-Salem, announced that it would be opening a big facility in Greensboro and bringing 330 jobs to the city.

INACTIVE